Evaxion reports new data supporting EVX-04 vaccine for acute myeloid leukemia

• Evaxion will present new preclinical data on EVX-04, its off-the-shelf acute myeloid leukemia vaccine, at ASH in New Orleans, December 12-15, 2026.
• Findings support broad patient coverage and consistent target expression across disease stages; the vaccine induced target-specific immune responses in humanized mice.
• The results build on findings presented at ASH 2025 showing vaccine-specific immune responses and tumor growth inhibition in mouse models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040900OMX_____CNEWS_EN_GNW1001301754_en) on November 04, 2026, and is solely responsible for the information contained therein.